An Open Label Positron Emission Tomography (PET) Study With (11C)Flumazenil to Determine Central GABAA Receptor Occupancy of AZD6280 After Oral Administration to Healthy Volunteers.

Trial Profile

An Open Label Positron Emission Tomography (PET) Study With (11C)Flumazenil to Determine Central GABAA Receptor Occupancy of AZD6280 After Oral Administration to Healthy Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Dec 2010

At a glance

  • Drugs AZD 6280 (Primary) ; Flumazenil
  • Indications Anxiety disorders
  • Focus Pharmacokinetics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 09 Dec 2010 Actual end date (Sep 2008) added as reported by ClinicalTrials.gov.
    • 12 Nov 2008 Trial end date updated, and final date for collection of primary outcome data updated in Trial Comments.
    • 12 Nov 2008 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top